health 🔬 Blood test could skip chemo for some breast cancer patients
Researchers identified a blood biomarker that might let hormone receptor-positive breast cancer patients skip chemo. The study involved 1,556 women under 55 at The University of Kansas Cancer Center and Emory University. Findings showed low anti-Müllerian hormone (AMH) levels meant no benefit from chemotherapy for many. This offers a more biologically meaningful way to assess ovarian reserve than age or menopausal status. Future trials are needed, but this points toward personalized cancer treatment. 🔬